Research published in 2023 has demonstrated the efficacy of sarilumab for IL-6 blockade in polymyalgia rheumatica and of secukinumab for IL-17 blockade in giant cell arteritis (GCA). Furthermore, preliminary results with human monocyte-derived suppressive cells suggest the potential of cellular therapeutics for the treatment of GCA.

中文翻译：

---

风湿性多肌痛和巨细胞动脉炎的治疗进展

2023 年发表的研究证明了 sarilumab 对风湿性多肌痛的 IL-6 阻断的功效，以及苏金单抗对巨细胞动脉炎 (GCA) 的 IL-17 阻断的功效。此外，人类单核细胞来源的抑制细胞的初步结果表明细胞疗法具有治疗巨细胞动脉瘤的潜力。